Tarsus Pharmaceuticals

TARS

Market cap $2.88B

Tarsus Pharmaceuticals has performed an aggressive marketing push for Xdemvy in Demodex blepharitis, with early signs of payoff seen, as sales now exceed SG&A expense. The company has appointed star biotech executive David Pyott, former CEO and Chairman of Allergan Inc, to the Board. TARS has H1'27 clinical catalysts from trials of lotilaner in Lyme-disease prevention/tick-killing and ocular rosacea.

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs.

An executive at Tarsus Pharmaceuticals sold 12,274 shares for a transaction value of approximately $839,000, based on a weighted average price of $68.36 per share across three days ending March 19, 2026. The transaction involved only direct ownership; no indirect entities or derivative securities were reported.

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of the People's Republic of China.

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

This eye drops stock is building a cup base following the biopharmaceuticals earnings report. Wall Street sees profit on its horizon.

IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

Tarsus Pharmaceuticals remains a Strong Buy, driven by Xdemvy's robust growth and management's $2B+ peak sales target. FY 2025 revenue surged 150% to $451M, with 2026 guidance at $670–$700M and 93% gross margins, though profitability is now expected in 2027. Xdemvy's US market penetration is just 5.6%, with international launches in China (2026) and Europe (2027) set to drive further growth.

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.6 per share a year ago.